Ann: VIRALEZE relaunched by LloydsPharmacy in the UK, page-242

To elicit an immune response ( antigen recognition and antibody response), the nasal vaccine active ingredient ( ie an antigen to the immune system) has to get into the blood or lymph systems to interact with the various cells and components that comprise the circulating immune system.

By complexing the nasal vaccine active ingredient with a macromolecule such as DEP, you will prevent cell entry and therefore immune activation. This applies to all external membranes, incl nasal mucus membranes and the vast Alveolar membrane complex of the lungs.

Remember, one of the important features about Viraleze (and Vivagel) is that active ingredient, SPL7013, is a macromolecule demonstrated NOT to cross these cell membranes. It is precisely this characteristic that is mis-understood by those ( incl TGA!) who were trying to claim that it is pharmocologically active, which, by definition, it is not ( ie it does not directly interact with the body's physiological processes).